David Day and a lifetime of missed moments
8 June 2018
“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.” Jenny, David’s wife.
When David lost his life last year, he was 33, with three daughters under six.
David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why.
The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.
Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.
Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.
David Day, was one such patient —a lovely young father with a wonderful family — who died last year.
The most agonising thing about patients like David is that at present, we just don’t know why they super progress.
Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.
Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.
By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.
While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.
We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.
David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.
Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.
In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.
After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin — with up to 30 more in his liver. Even though immune cells were present, David was super progressing.
As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.
On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.
“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.
Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression.
Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.
MIA joins Sydney Health Partners
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Congratulations Dr Hansol Lee
Promising young MIA researcher conferred with University of Sydney PhD.
Olympians join forces for melanoma warning
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
Aussies urged to mark start of summer by checking their skin
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
AMC2021 conference wrap-up
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Journalist and news reader Peter Overton our new National Ambassador
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research into importance of skin surveillance to save lives from melanoma
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
Game On Mole - saving lives this summer
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
Melanoma March physical events in 2022
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Community Fundraising Wrap Up July-Sept 2021
Read more about the wonderful MIA community fundraising initiatives held recently.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Melanoma Bike Bash 2021: What a ride!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
MIA researchers awarded $7.2m in NHMRC grants for health research
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.